Ocriplasmin - Biologic Drug Details

Summary for ocriplasmin

Tradenames:	1
Patents:	3
Applicants:	1
BLAs:	1
Recent Clinical Trials:	See clinical trials for ocriplasmin

Recent Clinical Trials for ocriplasmin

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Wagner Macula & Retina Center	Phase 2
Katholieke Universiteit Leuven	Phase 1
Universitaire Ziekenhuizen Leuven	Phase 1

See all ocriplasmin clinical trials

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. General brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for ocriplasmin Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for ocriplasmin Derived from Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Thrombogenics Inc.	JETREA	ocriplasmin	Injection	125422		2020-12-21	Company disclosures
Thrombogenics Inc.	JETREA	ocriplasmin	Injection	125422		2022-12-06	Company disclosures
Thrombogenics Inc.	JETREA	ocriplasmin	Injection	125422		2022-12-06	Company disclosures

3) Low Certainty: US Patents for ocriplasmin Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Thrombogenics Inc.	JETREA	ocriplasmin	Injection	125422		2032-04-02	Patent claims search
Thrombogenics Inc.	JETREA	ocriplasmin	Injection	125422		2031-10-25	Patent claims search
Thrombogenics Inc.	JETREA	ocriplasmin	Injection	125422		2032-04-02	Patent claims search
Thrombogenics Inc.	JETREA	ocriplasmin	Injection	125422		2032-04-02	Patent claims search
Thrombogenics Inc.	JETREA	ocriplasmin	Injection	125422		2033-03-14	Patent claims search

International Patents for ocriplasmin

Country	Patent Number	Estimated Expiration
China	100577202
Norway	20121169
Japan	5426063
Norway	20052988
United Kingdom	0116702
Hungary	S1300040

Supplementary Protection Certificates for ocriplasmin

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
SPC/GB13/048	United Kingdom		PRODUCT NAME: JETREA - OCRIPLASMIN; REGISTERED: UK EU/1/13/819/001 20130313
92255	Luxembourg		PRODUCT NAME: OCRIPLASMINE ET SES DERIVES PHARMACEUTIQUEMENT ACCEPTABLES(JETREA)
2013/033	Ireland		PRODUCT NAME: OCRIPLASMIN; REGISTRATION NO/DATE: EU/1/13/819/001 20130313
CA 2013 00047	Denmark		PRODUCT NAME: MIKROPLASMIN HERUNDER OCRIPLASMIN; REG. NO/DATE: EU/1/13/819/001 20130313
CR 2013 00047	Denmark		PRODUCT NAME: MIKROPLASMIN HERUNDER OCRIPLASMIN; REG. NO/DATE: EU/1/13/819/001 20130315
13C0041	France		PRODUCT NAME: OCRIPLASMINE; REGISTRATION NO/DATE: EU/1/13/819/001 20130313